Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Abeer, Shaaban"'
Autor:
Amit Goyal, Sophie Nicholls, Andrea Marshall, Natalie Hammonds, Duncan Wheatley, Beatrix Elsberger, Janice Rose, Helen-Teresa Edwards, Roeum Butt, Abeer Shaaban, Shama Puri, Samreen Ahmed, Tara Homer, Luke Vale, Julie Bruce, Sophie J. Gasson, Helen Higgins, Janet A. Dunn
Publikováno v:
Cancer Research. 83:OT1-09
Background: For patients who are node positive at presentation and are found to have a complete nodal tumour response (ypN0) post-neoadjuvant chemotherapy (NACT), we do not yet know whether local axillary therapy can be modified based on the response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::feecd0043f694b5f1f466879074deae0
https://doi.org/10.1158/1538-7445.sabcs22-ot1-09-02
https://doi.org/10.1158/1538-7445.sabcs22-ot1-09-02
Autor:
Kristina Petrovic, Joseph Robinson, Katharine Whitworth, Elizabeth Jinks, Abeer Shaaban, Steven P Lee
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0224015 (2019)
Engineering T-cells to express receptors specific for antigens present on tumour tissue is proving a highly effective treatment for some leukaemias. However, extending this to solid tumours requires antigens that can be safely and effectively targete
Externí odkaz:
https://doaj.org/article/57c7a75adfd24f708ea3a802e99514de
Autor:
Danielle O'neill, Kirstie Rice, Anjali Bhatnagar, Daniel Kearns, Fedor Berditchevski, Alaa El‑Ghobashy, Abeer Shaaban
Publikováno v:
Oncology Letters. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eec0e87e69d3de2ee341e2a023fb2e6a
https://doi.org/10.3892/ol.2023.13763
https://doi.org/10.3892/ol.2023.13763
Autor:
Mohamed Zaakouk, Aisling Longworth, Mervat El Deftar, Noha Ezzat, Emad Elgemeie, Abeer Shaaban
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 23:1785-1790
Breast cancer (BC) in non-Caucasian females is understudied and its management is based on Caucasian data. 30 % of the West Midlands females are non-Caucasian. We aimed to elucidate the pathologic features, molecular profile, and outcome of non-Cauca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a226c23c7c876444aff98acbe65a94c1
https://doi.org/10.31557/apjcp.2022.23.5.1785
https://doi.org/10.31557/apjcp.2022.23.5.1785
Autor:
Cliona Clare Kirwan, Bridget Hilton, Karen Clements, Hilary Stobart, Matthew Wallis, Senthurun Mylvaganam, Elena Provenzano, Anthony Maxwell, Nisha Sharma, Abeer Shaaban, David Dodwell, Joanne Dulson-Cox, Elinor Sawyer, Olive Kearins, Samantha Brace-McDonnell, Sarah Pinder, Alastair M Thompson
Publikováno v:
Cancer Research. 82:P1-22
Background: Disparity between mammographic and pathological sizing of DCIS can lead to surgical overtreatment, with poor cosmetic outcomes of breast conservation surgery (BCS) or inappropriate mastectomy versus undertreatment, with subsequent need fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64558ee80d2e113c1afb37370ee83b6
https://doi.org/10.1158/1538-7445.sabcs21-p1-22-01
https://doi.org/10.1158/1538-7445.sabcs21-p1-22-01
Autor:
Amit Goyal, Sophie Cramp, Andrea Marshall, Duncan Wheatley, Natalie Hammonds, Shama Puri, Tara Homer, Luke Vale, Roeum Butt, Romaana Mir, Janice Rose, Helen Teresa Edwards, Samreen Ahmed, Abeer Shaaban, Beatrix Elsberger, Julie Bruce, Sophie Gasson, Valerie Speirs, Jacqui Shaw, Helen Higgins, Janet Dunn
Publikováno v:
Cancer Research. 82:OT1-04
Background: For patients who are node positive to start at presentation and are found to have a complete nodal tumour response (ypN0) post neoadjuvant chemotherapy (NACT), we do not yet know whether local axillary therapy can be modified based on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb69393a4e9da940b5b1efbe9f9b98d9
https://doi.org/10.1158/1538-7445.sabcs21-ot1-04-01
https://doi.org/10.1158/1538-7445.sabcs21-ot1-04-01
Autor:
Karen Clements, Anthony Maxwell, Bridget Hilton, Matthew Wallis, Cliona Kirwan, Hilary Stobart, Elena Provenzano, Nisha Sharma, Janet Litherland, Abeer Shaaban, David Dodwell, Joanne Dulson-Cox, Elinor Sawyer, Senthurun Mylvaganam, Olive Kearins, Samantha Brace-McDonnell, Sarah Pinder, Alastair Thompson
Publikováno v:
Cancer Research. 82:P1-22
Background The variable natural history of ductal carcinoma in situ (DCIS) is poorly understood. The aim of this retrospective cohort study was to determine the outcomes of women who were diagnosed through the English National Health Service Breast S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20e2e4bfa1178583102012fb64e17c14
https://doi.org/10.1158/1538-7445.sabcs21-p1-22-06
https://doi.org/10.1158/1538-7445.sabcs21-p1-22-06
Autor:
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, Angela Cramer, Andrew Hanby, Abeer Shaaban, Emad Rakha, Anne Armstrong, Ramsey Cutress, David Dodwell, Marie Emson, Abigail Evans, Sue Hartup, Kieran Horgan, Stuart McIntosh, Jay Naik, Samkaran Narayanan, Jane Oii, Anthony Skene, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:P2-13
Background: EPHOS-B is a multi-centre randomized trial designed to investigate whether anti-HER2 therapy given 11 days pre-surgery inhibited proliferation and/or increased apoptosis in HER2-positive early breast cancer. Significant differences in Ki6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e00e6d4ba5bcb356c2aff20c4664e2f5
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-08
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-08
Autor:
Iain Macpherson, Stuart McIntosh, Lucy Kilburn, Holly Tovey, Sarah Kernaghan, Katie Goddard, Indrani Bhattacharya, Clinton Boyd, Charlotte Coles, Cliona Kirwan, Mairead Mackenzie, Ciara O’Brien, Alistair Ring, Claire Snowdon, Hilary Stobart, Duncan Wheatley, Andrew Wardley, Abeer Shaaban, Peter Hall, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:OT2-05
Background The presence or absence of residual disease following neoadjuvant systemic anti-cancer therapy (neoSACT) for HER2-positive early breast cancer (HER2+ EBC) provides powerful prognostic information that may guide subsequent adjuvant treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a21cd1f2ba7e31cfd59954e7383a662
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
Autor:
Muibat, Haruna, Adetola Olubunmi, Daramola, Nicholas Awodele, Awolola, Nahla Mustafa, Badr, Adekunbiola Aina Fehintola, Banjo, Abeer, Shaaban
Publikováno v:
ecancermedicalscience. 16
Androgen receptor (AR) is one of the predominant nuclear hormone receptors in invasive breast cancer and can be explored as a biomarker of response for targeted anti-androgen therapy, especially in the setting of triple negative breast cancer (TNBC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0a8c033411cf44f02e6a7a609cfad20
https://doi.org/10.3332/ecancer.2022.1452
https://doi.org/10.3332/ecancer.2022.1452